News
Public · Published
Hims & Hers teases November launch of Peptides+
Hims & Hers Health said it plans to launch its Peptides+ product category at the end of the month. CEO Andrew Dudum said it will include glutathione, NAD, sermorelin and B-12. He said further products, including BPC-157 and TB-500, would be offered when regulations allow them.
Published:
Updated:
What happened
Hims & Hers Health said it plans to launch its Peptides+ product category at the end of the month. CEO Andrew Dudum said it will include glutathione, NAD, sermorelin and B-12. He said further products, including BPC-157 and TB-500, would be offered when regulations allow them.
Confirmed
Global impact / market context
The near-term launch could give Hims & Hers another category to sell through its telehealth business, while its U.S. peptide and fulfillment facilities may support domestic production and delivery. Revenue and costs will depend on which products regulators permit and how customers respond.
Analyst inference
The announcement follows an October interim HHS policy allowing compounding pharmacies to make certain popular but unapproved peptides. This is temporary regulatory permission, not broad approval; the article says further products depend on regulatory allowance, making the product range subject to policy changes.
Confirmed
What to watch
- Whether Peptides+ launches at the end of the month with the four named ingredients, and whether the company gives details on availability, pricing or sales. Analyst inference
- Regulatory decisions on BPC-157 and TB-500, which the CEO said would be offered only when permitted, will determine whether the planned range can expand. Confirmed
- Any company updates on production capacity or fulfillment could clarify whether its U.S. facilities can support the launch without materially increasing operating costs. Analyst inference